Acutaas Chemicals — triple-digit profit growth, now betting on batteries and chips too
Acutaas Chemicals Limited (formerly Ami Organics Limited)
Snapshot
Acutaas Chemicals (renamed from Ami Organics in the last year) makes advanced pharmaceutical intermediates — the specialised building-block chemicals that go into making finished medicines — and is now expanding into battery chemicals and semiconductor materials. CMP ₹3,497, just 6.5% off its 52-week high, and 211% above its 52-week low — the stock is up roughly 3x over the last year. Over the last 12 months it’s had 18 volume-spike days, 12 of them up, including a +10% day and several +7-8% days. The one-line catalyst: two consecutive quarters of 100%+ profit growth, backed by a genuine multi-front expansion — a completed acquisition of a South Korean semiconductor-materials company and a first-in-India battery-chemicals plant — have kept turning up on almost every big move date.
As of 2026-07-14 — BSE filings, screener.in financials, Yahoo daily chart.
The verdict box
| Check | Reading |
|---|---|
| The move | ~+3x over 12 months; 18 volume-spike days, 12 up / 3 down (1 mixed), including a +10% day (24 Nov 2025) and clusters around each quarterly result |
| Catalyst type | Hard corporate event — repeated results beats (Q3 PAT +134% YoY, Q4 PAT +114-122% YoY) plus a completed cross-border acquisition |
| Evidence strength | HARD — board-approved results press releases and the acquisition-completion filing all read in full |
| Timing fit | Clean for the two biggest results-driven spikes (28 Jan, 30 Apr); the most recent spike (29 Jun) doesn’t line up with a single dated filing — flagged as a weaker fit |
| Sector confirmation | Not conclusively checked — theme-search tooling returned unrelated results; Acutaas’s specific three-segment diversification (pharma + battery + semiconductor chemicals) isn’t shared by an obvious basket of listed peers, so this reads as company-specific rather than sector-wide |
| Reflected in financials yet | Partially — the pharma-intermediates growth is already showing up in reported numbers (still 88% of revenue); the battery-chemicals and semiconductor bets are early-stage and not yet meaningfully reflected in the P&L |
| Catalyst Conviction | 8/10 |
The evidence says this company has posted genuinely extraordinary, repeated profit growth while simultaneously building two new growth legs (batteries, semiconductors) — that’s a strong structural case — but the valuation is now rich (P/E 80.5) and a recent tax-authority search plus declining promoter holding are real, open items worth watching rather than dismissing.
In plain English
Acutaas makes the specialised chemical ingredients (called intermediates) that pharmaceutical companies need to manufacture finished drugs — mostly replacing imports from China and Europe. That’s still 88% of what the company sells, and it’s been growing fast: revenue up 43% and profit more than doubling (up 134%) in the December 2025 quarter compared to a year earlier, then profit up over 100% again in the March 2026 quarter. Two back-to-back quarters of that kind of growth is genuinely rare, and both results announcements landed right on top of the stock’s biggest jumps — the market rewarding real, delivered numbers, not a promise.
On top of that core business, the company has been placing two new, much earlier-stage bets that explain why investors are willing to pay up for the stock rather than treat it as a one-trick pharma-chemicals story. First, it became India’s first domestic manufacturer of electrolyte additives — specialised chemicals used inside lithium-ion batteries — commercialising a new plant in Gujarat, a direct play on India’s electric-vehicle and battery-manufacturing buildout. Second, in February 2026 it completed the acquisition of a controlling 75% stake in a South Korean company called Indichem, moving the company into semiconductor-industry chemicals — a genuinely different, high-value customer base. Both of these are still small relative to the core pharma business today, which is exactly why they matter for the catalyst read: the market isn’t just paying for what Acutaas earns now, it’s paying for the option that either of these two new legs becomes a second or third real growth engine over the next several years.
The most recent big move (29 June, the stock’s largest volume day in months) is the one piece I can’t tie to a single clean announcement. What I did find: two days earlier, India’s tax authorities (the GST Anti-evasion Department) conducted a search at the company’s main Surat facility — the company disclosed it immediately, said there was “no material impact,” and confirmed the search concluded the very next day. It’s plausible that uncertainty clearing, combined with a wave of financial-media coverage in the following days repackaging the pharma-plus-battery-plus-semiconductor growth story for a wider audience, is what drove the 29 June move — but I want to be upfront that this is the weakest-evidenced part of this read, not a confirmed single trigger.
Two things worth knowing before treating this as a clean story: the stock now trades at a P/E of over 80, meaning a lot of future growth is already priced in, and promoter (founder) shareholding has declined by about 6.75 percentage points over the last three years — worth distinguishing between routine dilution (from raising capital for the new plants/acquisitions) and actual promoter selling, which this search did not resolve either way.
The hunt — what the price action shows
| Date | Volume vs 50-day avg | Move | Direction |
|---|---|---|---|
| 2025-10-17/20 | 7.1x, 4.6x | +6.0%, +7.1% | up |
| 2025-11-24 | 6.0x (largest) | +10.0% | up |
| 2026-01-28/29 | 4.3x, 4.0x | +7.8%, +3.9% | up |
| 2026-03-24 | 4.0x | +7.4% | up |
| 2026-04-01/02 | 3.8x, 2.7x | −8.9%, −9.5% | down |
| 2026-04-30 | 5.7x | +3.7% | up |
| 2026-06-29 | 4.9x (most recent) | +8.1% | up |
Note the sharp two-day drop on 1-2 April (−8.9%, −9.5%) — the stock gave back a chunk of its March rally before recovering on 30 April results day; that’s a real, mixed signal worth flagging alongside the mostly-up pattern (12 up-spikes vs 3 down over the full 14-month lookback).
The hunt — what we found
1. Q3 FY26 results, 28 January 2026 (HARD, clean same-day timing fit) Read in full from the press-release filing: “Q3 FY26 Revenue from Operation at ₹3,932mn, up 43.0% YoY… Q3 FY26 PAT crosses ₹1,000mn milestone, reaching ₹1,062mn, up 133.7% YoY.” Gross profit was up 76.1% YoY — margins expanding, not just volume. The stock jumped 7.8% the same day on 4.3x average volume, and news coverage the same week flagged “Acutaas Chemicals Plans Rs 350 Crore Investment Drive with Major Capex and Joint Venture Expansion” — the market reacted to both the beat and the forward capital-deployment plan together.
2. Indichem (South Korea) acquisition completed, 11 February 2026 (HARD, reasonably clean timing fit) Read in full from the BSE filing: “Acutaas Advance Material Limited… has acquired 75% of shareholding stake in the joint venture company, Indichem Inc. … Pursuant to this, Indichem Inc. has become a step-down subsidiary of the Company.” This followed an original JV agreement from June 2025 — the completion of the acquisition (not just the intent) is the harder, more decisive event. A ~2.4% spike on 10 February (the day before, likely on anticipation/broker coverage — Kotak Securities recommended the stock that same day) suggests the market had some advance visibility.
3. Q4 FY26 / full-year results, 30 April 2026 (HARD, clean same-day timing fit) Filed and approved at a board meeting the same day; subsequent news confirms “PAT Surges 114%” (2 May) and later “FY26 PAT surges 122% to ₹3,564 Mn… Guides 25% FY27 Growth” (6/18 May). The stock moved 3.7% on 5.7x volume the same day, with continued follow-through into early May (3.2% move, 4 May) as the results were digested and covered further — including an Indian Express piece titled “Acutaas Chemicals: The specialty chemicals story the market is re-rating fast” (18 May).
4. GST Anti-evasion search, 22-23 June 2026, resolved quickly (HARD but negative-then-neutral, weak direct timing fit to the 29 June spike) Read in full from both filings: on 22 June, “the Central Goods & Service Tax & Central Excise (CGST & CE), Anti-evasion Department, Surat, Gujarat… initiated inspection/search proceedings at the Company’s Sachin facility.” The company stated “no material impact on the financials, business operations.” The very next filing (23 June) confirms the search “concluded” the same day. This is a real, dated, negative-leaning event that resolved fast — not the direct cause of the 29 June rally (6 days later), but plausibly a cleared overhang sitting in the background.
5. Insider/SAST bucket — only two filings, both routine “Closure of Trading Window” notices (25 Mar, 26 Jun) ahead of results. No promoter or insider on-market buying found in this window — worth noting given the multi-year decline in promoter holding flagged by screener.in.
Catalyst quality — is it durable?
Structural — this is the strongest durability case among recent catalyst reads. The core pharma-intermediates business isn’t a one-quarter fluke: it’s been compounding at roughly 46% CAGR over five years per screener’s own numbers, and just posted two consecutive quarters of 100%+ profit growth on top of that base — an acceleration, not a plateau. Layered on top are two genuinely new, high-optionality growth vectors (battery electrolyte additives, semiconductor materials via Indichem) that diversify the company away from being a single-theme pharma-intermediates play. Both are the kind of thing that, if they scale, keep generating good news for years rather than one quarter.
The counterweight: a P/E above 80 means the market has already priced in a great deal of that future growth — management’s own FY27 guidance of “just” 25% growth (versus the 100%+ pace just delivered) could itself become a source of disappointment if the market is extrapolating the recent pace rather than the guided one. Declining promoter shareholding (−6.75 percentage points over 3 years) and the still-fresh GST search are real, open items that a reader should track rather than assume away.
Sector confirmation: inconclusive. The theme-search tool used for this check returned unrelated results (a tooling issue, not a negative finding), so I’m not claiming a sector-wide read either way — this should be treated as a company-specific story until independently checked against other Indian pharma-intermediate or specialty-chemical names.
What would confirm or kill this read
- Q1 FY27 results — does growth decelerate toward the guided 25%, or does the company keep beating its own guidance the way it has for the last two quarters?
- Any follow-up from the GST anti-evasion search — the company says no material impact, but a formal notice or penalty following the concluded search would be a genuine new negative catalyst to re-check.
- Revenue contribution from Indichem (semiconductor) and the battery-chemicals plant — watch for these to move meaningfully beyond the current ~12% non-pharma-intermediates share; that’s the real test of whether the “three megatrends” story is delivering or still mostly narrative.
- Promoter shareholding trend — whether the multi-year decline continues, stabilises, or reverses in the next shareholding-pattern disclosure.
Sources
- Screener.in: https://www.screener.in/company/ACUTAAS/consolidated/
- BSE filings read in full: Q3 FY26 press release (28 Jan 2026), Indichem acquisition-completion filing (11 Feb 2026), GST search intimation + conclusion filings (22-23 Jun 2026)
- News: The Economic Times (multiple “smallcap stocks” listicle mentions, Oct 2025-Jul 2026), scanx.trade (28 Jan capex/JV plan, 11 Feb/16 Feb Indichem, 2 May/6 May/18 May Q4 results), Business Standard (5 Mar/17 Mar/24 Mar rally coverage, 9 Jul volume note), Indian Chemical News (16 Feb Indichem), The Indian Express (18 May re-rating piece), Value Research (6 Apr valuation caution), web-search corroboration of the “three megatrends” (pharma/battery/semiconductor) framing referenced in NDTV Profit’s 30 June coverage (article itself not directly fetchable)
- Could not access: the NDTV Profit “three megatrends” article directly (site blocked automated fetch — corroborated via secondary sources instead); a reliable sector-wide theme-confirmation check (tooling returned unrelated results)